A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment by Samalin, E. et al.
HAL Id: hal-02310075
https://hal.archives-ouvertes.fr/hal-02310075
Submitted on 9 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
A phase I-trial assessing several schedules of Oral S-1
combined with fixed doses of Oxaliplatin and Irinotecan
in patients with advanced or metastatic digestive
adenocarcinoma as first- or second-line treatment
E. Samalin, S. Thezenas, J.-P Delord, A. Italiano, D. Smith, F. Portales, T.
Mazard, E. Assenat, S. Poujol, I. Solassol, et al.
To cite this version:
E. Samalin, S. Thezenas, J.-P Delord, A. Italiano, D. Smith, et al.. A phase I-trial assessing several
schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced
or metastatic digestive adenocarcinoma as first- or second-line treatment. ESMO 17th World Congress
on Gastrointestinal Cancer, Jul 2015, barcelona, Spain. pp.iv47-iv47, ￿10.1093/annonc/mdv233.161￿.
￿hal-02310075￿
posters
P 161 A phase I-trial assessing several schedules of Oral S-1
combined with fixed doses of Oxaliplatin and Irinotecan in
patients with advanced or metastatic digestive
adenocarcinoma as first- or second-line treatment
E. Samalin1, S. Thezenas1, J.-P. Delord2, A. Italiano3, D. Smith4, F. Portales5,
T. Mazard1, E. Assenat1, S. Poujol1, I. Solassol1, S. Khier6, P. Chalbos1, M. Ychou1
1Institut Régional du Cancer de Montpellier, Montpellier, France
2Institut Claudius Regaud, Toulouse, France
3Institut Jean Bergonié, Bordeaux, France
4University Hospital, Bordeaux, France
5Institut Régional du Cancer, Montpellier, France
6Université de Montpellier, Montpellier, France
Introduction: S-1 is a fourth-generation oral fluoropyrimidine based on the
combination of Tegafur, converted to 5-fluorouracil (5-FU) in the liver by the
cytochrome P450 2A6, with two 5-FU biochemical modulators, namely Gimeracil and
Oteracil. Combined S-1 with Irinotecan (Iri) or Oxaliplatin (Ox) was assessed in Asian
populations according to biweekly schedules with an acceptable toxicity and efficacy
(Chon et al, 2011, Cancer Chemother Pharmacol; Hong et al, 2010, Cancer Chemother
Pharmacol). SIRINOX is a phase I multicenter trial. Primary objective is to determine
the maximum tolerated dose in both SIRI and SIRINOX regimens and the
recommended phase II dose of Oral S-1 combined with a fixed dose of Ox and Iri in a
biweekly schedule. Secondary objectives are safety, objective response rate,
progression-free and overall survival. Ancillary analyses will be conducted on S-1 and
Iri pharmacokinetics, as well as on the mutational status of the UGT1A1, DPD and
CYP2A6 genes.
Methods: Concerning the SIRI schedule, a standard 3 + 3 design with a dose-escalation
of four dose-levels of S-1 is planned (25, 30, 35 and 40mg/m2). S-1 is delivered twice a
day from day 1 to day 7, followed by a 7-day recovery period, with a fixed dose of
180mg/m2 Iri over 90 minutes IV, on day 1 of each cycle. Three additional patients will
be included if a dose limiting toxicity is reported. For the SIRINOX schedule, a
standard 3 + 3 design is planned, with 5 dose-levels of S-1 (20 to 40mg/m2, with 5mg/
m2 increments) depending on the SIRI results. Fixed doses of Ox (85mg/m2 over 120
minutes IV) and of Iri (180mg/m2 over 90 minutes IV) will be delivered at day 1 of
every cycle. G-CSF will be given systematically from day 8 to day 13. The first patient
was included recently and treated at the first level. The recommended phase II dose will
be tested in an expansion cohort of 10 additional patients. Given the therapeutic
potential and reduced toxicity advantages of S-1 compared with other
fluoropyrimidines, this trial was developed to propose an alternative regimen to
FOLFIRI and FOLFIRINOX.
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